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OBJECTIVE: Hemophagocytic lymphohistiocytosis in adults is largely underdiagnosed. To improve the rate and
accuracy of diagnosis in adults, the clinical and laboratory characteristics of hemophagocytic lymphohistiocy-
tosis were analyzed in and compared between adults and children in a Chinese cohort.
METHOD: Data from 50 hemophagocytic lymphohistiocytosis patients, including 34 adults and 16 children who
fulfilled the 2004 hemophagocytic lymphohistiocytosis diagnostic criteria, were collected and analyzed.
RESULTS: 1. Etiological factors: The proportion of Epstein-Barr virus infection was lower in adults compared
with children, whereas fungal infection and natural killer/T cell lymphoma were more frequent in adults
(Po0.05). 2. Clinical manifestations and laboratory findings: Over 90% of adults and pediatric patients
presented with fever, thrombocytopenia and high serum ferritin levels. However, in adults, the proportions
of hepatomegaly, splenomegaly and jaundice were much lower (Po0.01) than in children, and serous
cavity effusion was more frequent in adult patients (Po0.05). More children had hemoglobin o90 g/L, total
bilirubin419 mmol/L and lactate dehydrogenase4500 U/L compared with adults (Po0.05). 3. The time interval
from the onset of symptoms to clinical diagnosis was significantly shorter in pediatric patients than in adults
(Po0.05).
CONCLUSIONS: Certain clinical features were different between the two groups. The less characteristic clinical
presentation of hemophagocytic lymphohistiocytosis in adults may make the disease more difficult to diagnose.
Our findings suggest that hemophagocytic lymphohistiocytosis should be considered when an adult patient
presents with the above-mentioned symptoms.
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’ INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is a severe
inflammatory disorder characterized by a significant accumu-
lation of activated CD8+ T lymphocytes and histiocytes in
the bone marrow (BM) and lymphoid tissues. The cytokine
storm resulting from the accumulation of activated immune
cells leads to fever, hepatosplenomegaly, impaired liver
function and other clinical and laboratory manifestations of
HLH (1-3). Classically, HLH is divided into primary or
familial HLH (FHL) and secondary HLH (sHLH). FHL,
which is an autosomal recessive disease, is caused by
mutations in the genes encoding the molecules involved in
the granule exocytosis machinery of cytotoxic T lymphocytes
and natural killer (NK) cells. Although the pathogenesis of
sHLH is largely unknown, the two forms of HLH, or sHLH
and FHL, have similar clinical characteristics (1-3).
HLH is characterized by fever, hepatosplenomegaly,
bicytopenia or pancytopenia, hemophagocytosis in the BM
and lymphoid tissues, liver dysfunction and central nervous
system (CNS) symptoms (1-3). Infection is described as aDOI: 10.6061/clinics/2016(04)05
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major trigger of HLH development, and Epstein-Barr virus
(EBV) has been described as the dominant pathogen (1, 3).
Without effective treatment, many HLH patients die within 3
months. Treatment of HLH, whether in the FHL or the sHLH
form, has significantly improved due to early introduction of
immunochemotherapy (2, 4). Obviously, an early diagnosis
of HLH and a timely initiation of effective treatment are
crucial for improving the prognosis of HLH patients. To this
end, a good understanding of the clinical features of adult
HLH would be very helpful to clinicians for prompt diag-
nosis and effective treatment. Notably, however, previous
reports on HLH have mainly focused on pediatric HLH, and
current knowledge of HLH primarily originated from
observations of pediatric patients. Therefore, the clinical
features of adult HLH have not been well described. The
present retrospective clinical investigation was performed to
characterize the clinical and laboratory features of adult
HLH in a Chinese cohort and to compare adults and children
with HLH in this cohort.
Patients
A total of 86 patients diagnosed with HLH on admission or
by discharge from January 2008 to December 2012 in the
Departments of Hematology and Pediatrics of the Second
Hospital of Shandong University and Linyi People’s Hospital,
Shandong, China, were studied. Fifty of the 86 patients met the
2004 HLH diagnostic criteria (2); these individuals constituted
the cohort of the present study. A diagnosis of HLH was
made when five or more of the following eight criteria were
fulfilled: 1) fever; 2) splenomegaly; 3) cytopenia affecting at
least two of the three lineages in the peripheral blood
(hemoglobin o 90 g/L, platelets o100 109/L, neutrophils
o1.0 109/L); 4) hypertriglyceridemia and/or hypofibrino-
genemia (fasting triglycerides X3.0 mmol/L or X3 SDs,
fibrinogen p1.5 g/L or p3 SDs); 5) ferritin X500 mg/L; 6)
soluble CD25 (soluble IL-2 receptor)X2400 U/mL; 7) low or
absent NK cell activity; and/or 8) hemophagocytosis in the
BM, spleen or lymph nodes. Clinical, laboratory and imaging
data as well as information on etiological factors, such as
infections (including with EBV, cytomegalovirus (CMV) and
bacteria) or underlying diseases, from the 50 HLH patients
were collected and analyzed. Approval for this study was
obtained from the Ethics Committee of Shandong University.
According to the cut-off point for age (15 years old), the
patients were divided into an adult group and a pediatric
group. Patients who received therapy with steroids and/or
intravenous immunoglobulin (IvIG) were grouped into a
‘‘non-specific HLH protocols’’ group, and those who under-
went the 2004 HLH treatment protocol were grouped into an
‘‘HLH-2004 protocol’’ group.
Laboratory Tests
EBV serology test and EBV-DNA quantification. EBV
infection was determined by detecting serum anti-viral cap-
sid antigen (VCA)-IgG, anti-VCA-IgM, and anti-early antigen
(EA)-IgG using an anti-EBV antibody kit (EUROIMMUN
Medizinische Labordiagnostika AG, Lubeck, Germany) follow-
ing the procedures detailed by the manufacturer. EBV-DNA
was detected using the quantitative real-time polymerase chain
reaction (qRT-PCR) technique with a LightCycler 480/96
(fluorescence-based quantitative thermal cycler, Roche, Indiana-
polis, IN, USA) and EBV nucleic acid amplification fluorescence
detection kits (KAIJIE Biological Engineering Co. Ltd.,
Shenzhen, China) following the manufacturers’ protocols.
CMV serology test and CMV-DNA quantification. An
enzyme-linked immunosorbent assay (ELISA) was applied
to detect anti-CMV-IgM antibody and anti-CMV-IgG anti-
body in serum using anti-CMV antibody kits provided by
EUROIMMUN AG (Lubeck, Germany) and a BEP-2000
automatic microplate reader (Dade, Miami, FL, USA)
following the protocols provided by the manufacturers.
CMV-DNA in serum was quantified by the qRT-PCR method
using a CMV PCR Fluorescence Diagnosis Kit (Daan,
Guangzhou, China) and a LightCycler 480/96 fluorescence-
based quantitative thermal cycler (Roche, Indianapolis, IN, USA)
Detection of pathogenic bacteria and fungi. Blood samples
from the patients were cultivated for detection of pathogenic
bacteria and fungi using a BacT/ALERT 3D automated blood
culture system (bioMérieux Inc., Durham, NC, USA) and a
VITEK 2 compact microbial identification and susceptibility
analysis system (bioMérieux S.A, Marcy l’Etoile, France).
Hemophagocytosis identification. Smears of BMwere stained
with Wright-Giemsa, and identification of hemophagocytosis was
performed by hematopathologists. The histiocytes showing pha-
gocytosis of platelets, one or more intact erythrocytes or precur-
sors, neutrophils or granulocyte precursors, plasma cells, and/or
lymphocytes were counted as indicating hemophagocytosis.
Routine blood tests. Blood routine tests were performed
using a Sysmex XT-4000i Automated Hematology Analyzer
(Mundelein, IL, USA) and kits from Beckman Coulter
Trading Co. Ltd. (Shanghai, China).
Ferritin quantification. Ferritin in serum was quantified
using a ferritin test kit purchased from Roche Diagnostics
Corporation (Roche, Shanghai, China) and a Cobas e 601
analyzer in conjunction with ECL (Roche, Basel, Switzerland).
Other biochemistry tests. Quantification of serum lactate
dehydrogenase (LDH) and total bilirubin (TB) were performed
using a Beckman UniCels DxC 800 automatic biochemistry
analyzer (Brea, CA, USA) along with detection kits for LDH
produced by Beckman Coulter Systems Ltd. (Suzhou, China).
TB in serum was quantified by using a kit produced by Beijing
Leadman Biochemical Technology Co. Ltd. (Beijing, China).
Serum triglycerides, alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and gamma glutamyl transferase (g-GT)
were quantified using a Cobas C501 automatic biochemical
analyzer (Roche Diagnostics, Mannheim, Germany) and respec-
tive related detection kits (Mannheim, Germany). Fibrinogen
was measured using an STA Compact STAGO coagulation
analyzer along with a kit manufactured by DIAGNOSTICA
STAGO (Rue des Freres Chausson, Asnieres Cedex, France).
Splenomegaly, hepatomegaly, and lymphadenopathy in the
abdomen were evaluated by color Doppler ultrasonography.
Lymphadenopathy in the chest was determined by computed
tomography (CT).
The early response to treatment was evaluated by compar-
ing hemoglobin, platelets, neutrophils, ferritin, LDH and TB
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at diagnosis with the values after 2-3 weeks of HLH-2004 or
non-specific HLH protocol treatment.
Statistical Analysis. The variables were described as
follows: n, proportion and median. The categorical variables
were compared using the w2 test, and numeric variables were
compared using the Wilcoxon signed-rank test. All analyses
were performed using PASW Statistics 18.0, and a P value
less than 0.05 was considered statistically significant.
’ RESULTS
Characteristics of HLH patients
The HLH patients included 34 adults and 16 children.
There was no difference in the sex distribution (P40.05).
Etiological factors were different between the adult group
and the pediatric group (Po0.05). In particular, 2.9% of the
adults (1/34) had EBV infection, which was much lower than
the rate in the children (31.3%, or 5/16). However, the
proportions of fungal infection and NK/T cell lymphoma
were higher in adults compared with children (Po0.05).
There was neither parental consanguinity nor a family
history of HLH-like disease in any case. No genetic data
were available for any of the HLH cases.
A total of 19 patients were treated with the HLH-2004 pro-
tocol, and 31 patients were administered non-specific HLH pro-
tocol treatment. None received stem cell transplantation (SCT).
In all, 46% of patients (23/50) stopped treatment on their own,
and 6 patients died (4 adults and 2 children) within 2 weeks of
treatment initiation. In the remaining 21 cases, 12 individuals
(7 adults and 5 children) were treated with the HLH-2004
protocol, and 9 (8 adults and 1 child) were treated with the non-
specific HLH protocols. The results are shown in Table 1.
Clinical manifestations and laboratory findings in
HLH patients before treatment
The proportions of hepatomegaly, splenomegaly and
jaundice were much lower in adults than in children
(47.1% vs 93.8%, 61.8% vs 100.0%, and 41.2% vs 87.5%,
respectively, Po0.01). Meanwhile, serous cavity effusion was
present in 41.2% of adult patients, which was higher than the
rate (12.5%) in children (Po0.05).
In total, 38.2% of adults had hemoglobino90 g/L (Po0.05),
compared with 75.0% of children. Additionally, more children
than adults had TB419 mmol/L and LDH4500 U/L (87.5%
vs 41.2% and 93.8% vs 58.8%, respectively, Po0.05).
There were no differences in other clinical presentations
and laboratory findings between the groups (P40.05). The
results are shown in Table 2.
Time interval from onset to diagnosis and rate of
early response to treatment
Our results demonstrated that the time interval from the
onset of symptoms to clinical diagnosis was significantly
shorter in pediatric patients than in adult patients (7 days vs
11 days, Po0.05).
Among the remaining 21 patients, 12 (7 adults and 5 children)
were treated with the HLH-2004 protocol, and 9 (8 adults and
1 child) were treated with the non-specific HLH protocols. As
shown in Table 3, after 2-3 weeks of treatment with the HLH-
2004 protocol, the blood cells of the 12 patients (both adults and
children) had recovered to different degrees. At the same time,
serum ferritin and LDH levels had declined significantly in
children (Po0.05). Interestingly, the non-specific HLH treat-
ments also significantly reduced serum ferritin concentrations in
adult HLH patients (data not shown).
’ DISCUSSION
It has been previously reported that the onset age of FHL is
usually less than 2 years old (1-3), whereas sHLH can occur
at any age. In line with the earlier reports, our results showed
that the age of pediatric patients at onset ranged from
2 months to 3 years, with a median age of 1 year. Our current
knowledge of HLH has been largely obtained from studies of
pediatric HLH, and particularly FHL. As a result, the clinical
and laboratory features of adult HLH have not been fully
characterized and were only recently described more
extensively in larger reviews and studies. The present study
showed that adult and pediatric HLH patients share certain
clinical and laboratory features and triggering factors, although
important differences do exist. This study specifically compared
clinical manifestations and laboratory features of HLH in adults
with those in pediatric patients.
Table 1 - Characteristics of hemophagocytic lymphohistiocytosis patients (n, %).
Adult group (n=34) Pediatric group (n=16) w2 P
Sex: Male 20 (58.8) 8 (50.0) 0.344 0.558
Female 14 (41.2) 8 (50.0)
Age (years; median, range) 43 (15-77) 1 (0.2-3) / 0.000
Etiological factors
Bacterial infection 6 (17.6) 2 (12.5) 9.925 0.042
Fungal infection 2 (5.9) 0 (0.0)
EBV infection 1 (2.9) 5 (31.3)
NK/T cell lymphoma 3 (8.8) 0 (0.0)
Unknown cause 22 (64.7) 9 (56.2)
Treatment
HLH protocol* 11 (32.4) 8 (50.0) 5.737 0.125
Non-HLH protocol
Steroids 15 (44.1) 3 (18.8)
Steroids and immunoglobulin 5 (14.7) 5 (31.2)
Steroids and cyclosporine 3 (8.8) 0 (0.0)
2-3 weeks of follow-up
Abandonment of treatment 15 (44.1) 8 (50.0) 0.200 0.905
Death 4 (11.8) 2 (12.5)
Partial or complete response 15 (44.1) 6 (37.5)
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Infection is a major trigger of HLH, and in children, EBV is the
most common reason for HLH (1, 2, 5). As expected, we showed
that EBVwas the main infectious trigger of HLH in our pediatric
patients, with a proportion of 31.3%. Surprisingly, we found that
only 2.9% of the adult patients had HLH associated with EBV
infection (Po0.05). In contrast, fungal infection and NK/T cell
lymphoma were more common triggers in adults compared
with children (Po0.05). These findings suggest a significant
difference in triggering factors between adult and pediatric HLH
in our specific cohort of patient. Notably, these results are not in
line with the large recent review by Ramos-Casals in 2014 in
which EBV infection was reported to be a common trigger of
HLH in adults (6). However, 64.7% of the adults and 56.2% of
the children had HLHwith no identified etiological cause, so we
needed to expend extra effort to determine the possible causes of
sHLH in these groups.
It is well known that during the progression of HLH,
activated CD8+ T cells produce large amounts of interferon-
gamma (IFN-g), which in turn stimulates overactivation and
expansion of CD8+ T cells and macrophages. The activated T
cells and macrophages infiltrate and accumulate in the liver,
spleen, BM, lymph nodes and other organs or tissues, resulting
in hypercytokinemia and tissue/organ damage, which in turn
result in corresponding clinical manifestations (1,2,5,6). Typically,
HLH patients present with long-term fever, hepatosplenome-
galy, cytopenia, liver damage, jaundice, hemophagocytosis and
CNS involvement (8). In our study, we found that adults and
children with HLH shared the clinical manifestations of fever,
thrombocytopenia, liver dysfunction, and elevated ferritin levels.
However, adults with HLH less commonly presented with
splenomegaly, hepatomegaly and jaundice compared with
pediatric HLH patients. Interestingly, serous cavity effusion
was found to have a much higher incidence in adults (41.2%)
than in children (12.5%).
The differences observed in the degree of jaundice and in
the incidence of hepatomegaly and splenomegaly between
pediatric and adult patients may have been due to different
conditions triggering the onset of HLH.
Cytopenia is an important laboratory manifestation
observed in HLH, resulting from hemopoiesis suppression
by the highly elevated levels of inflammatory cytokines,
such as IFN-g released by activated T cells, and from the
Table 2 - Clinical and laboratory findings in adult and pediatric HLH patients at diagnosis (n, %).
Adult group (n=34) Pediatric group (n=16) w2 P
Clinical presentations
Fever 34 (100.0) 16 (100.0) 0.000 1.000
Hepatomegaly 16 (47.1) 15 (93.8) 10.068 0.002
Splenomegaly 21 (61.8) 16 (100.0) 8.267 0.004
Lymphadenopathy 9 (26.5) 7 (43.8) 1.493 0.222
Pulmonary involvement 23 (67.6) 8 (50.0) 1.438 0.230
Serous cavity effusion 14 (41.2) 2 (12.5) 4.112 0.043
Neurological symptoms 10 (29.4) 6 (37.5) 0.327 0.567
Hemorrhages 12 (35.3) 6 (37.5) 0.023 0.880
Jaundice 14 (41.2) 14 (87.5) 9.475 0.002
Urinary symptoms 5 (14.7) 0 (0.0) 2.614 0.106
Blood cell analysis
Hemoglobin o90 g/L 13 (38.2) 12 (75.0) 5.882 0.015
Platelets o100109/L 33 (97.1) 15 (93.8) 0.310 0.578
Neutrophils o1109/L 22 (64.7) 12 (75.0) 0.530 0.467
Hemophagocytosis in BM 30 (88.2) 13 (81.3) 0.441 0.507
Blood biochemistry
Ferritin 4500 mg/L 33 (97.1) 16 (100.0) 0.480 0.488
Fibrinogen p1.5 g/L 16 (66.7) 7 (43.8) 0.048 0.827
ALT 440 U/L 28 (82.4) 15 (93.8) 1.174 0.279
AST 440 U/L 30 (88.2) 16 (100.0) 2.046 0.153
g-GT 450 U/L 26 (76.5) 13 (81.2) 0.145 0.704
TB 419 mmol/L 14 (41.2) 14 (87.5) 9.475 0.002
LDH 4500 U/L 20 (58.8) 15 (93.8) 6.320 0.012
TG 43.0 mmol/L 15 (44.1) 7 (43.8) 0.001 0.981
Na o135 mmol/L 18 (52.9) 8 (50.0) 0.038 0.846
Ca o2 mmol/L 18 (52.9) 6 (37.5) 1.039 0.308
CRP 410 mg/L 15 (44.1) 11 (68.8) 2.645 0.104
BM: bone marrow; ALT: alanine aminotransferase; AST: aspartate aminotransferase; g-GT: gamma glutamyl transpeptidase; TB: total bilirubin; LDH: lactate
dehydrogenase; TG: triglycerides; CRP: C-reactive protein
Table 3 - Changes in laboratory findings between diagnosis and after 2-3 weeks of treatment with the HLH-2004 protocol in adult and
pediatric patients (medians).
Adult group (n=7) Pediatric group (n=5)
Pre-treatment Post-treatment P Pre-treatment Post-treatment P
Hemoglobin (g/L) 90.00 103.00 0.620 82.00 87.00 0.841
Platelet (109/L) 42.00 70.00 0.165 51.00 113.00 0.008
Neutrophil (109/L) 0.85 3.54 0.456 0.63 1.37 0.056
Ferritin (mg/L) 2000.00 407.10 0.053 1650.00 121.50 0.032
LDH (U/L) 1013.90 419.00 0.126 1511.00 299.50 0.008
TB (mmol/L) 17.65 12.83 0.383 110.50 16.67 0.056
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phagocytosis of blood cells by over-activated macrophages.
In our study, thrombocytopenia was common in both adults
(97.1%) and children (93.8%), highlighting that thrombocy-
topenia is a prominent clinical feature of not only pediatric
(8,9) but also adult HLH. However, cytopenia of multiple
lineages was less common in adults than in children.
Ferritin presents in every cell type and serves as a carrier
protein to store iron in a non-toxic form. An elevation of the
serum ferritin concentration is linked to other conditions, such
as infection, autoimmune and autoinflammatory disorders, and
cancer, in addition to HLH. Excessively activated macrophages
over-secrete ferritin, leading to the elevated serum ferritin levels
observed in HLH. Elevated serum ferritin is an important
marker not only for the diagnosis of HLH but also for the
evaluation of disease activity (7,9,11). Decreased serum ferritin
and LDH levels have been shown to reflect a good response to
HLH treatments (8,12). Similar to ferritin, LDH (a cytoplasmic
enzyme present in many cell types) is released upon cell
damage, and LDH levels have also been suggested as a
prognostic indicator of HLH (9). In the present study, we
observed elevated levels of serum ferritin in nearly all patients
and increased LDH levels in 58.8% of the adult and 93.8% of
the pediatric patients. In line with previous studies, our
findings showed that ferritin and/or LDH levels were
significantly decreased after 2-3 weeks of treatment in both
groups, and especially in pediatric patients, suggesting that
serum ferritin and/or LDH may function as sensitive markers
reflecting the early treatment response. It should be noted that
the platelet count may also be a parameter reflecting the early
response to disease treatment, given that in the present study,
depressed platelet counts in pediatric HLH patients had
increased after the first 2-3 weeks of treatment with both the
HLH-2004 protocol and non-specific HLH treatment.
CNS involvement is considered to be an independent
prognostic marker for pediatric HLH (13,15). Therefore, it is
important to determine the status of CNS involvement in HLH
patients at diagnosis. Previous studies demonstrated that 46%
and 47% of pediatric HLH patients in Korean and Chinese
cohorts, respectively, presented with CNS involvement (14,16).
In our cohort, 29.4% and 37.5% of adult and pediatric HLH
patients, respectively, showed CNS signs and symptoms at
diagnosis. The value of CNS involvement in predicting
prognosis in adult HLH patients needs to be further evaluated
in future prospective studies with larger cohorts.
There are limitations to the present study. For example,
we were unable to distinguish FHL from sHLH among the
investigated pediatric and adult patients because no genetic
data were available. Furthermore, the number of pediatric
HLH patients in this study was relatively small. However, the
incidences of the principal clinical and laboratory features in
our pediatric patients were consistent with those in previous
reports (1,2,5,7,17). Nevertheless, the retrospective nature
of this study and the cohort size limited the possibility of
prognostic analysis of clinical and laboratory parameters.
Altogether, the findings in this study demonstrate that
consistent with pediatric HLH, fever, thrombocytopenia, liver
dysfunction and elevated ferritin levels are common clinical
manifestations in adult HLH. In contrast, splenomegaly, hepato-
megaly and jaundice are less common and less severe in adults
than in children, suggesting that this phenotype is not as
common in adults with HLH. The time interval from onset to the
clinical diagnosis of HLH in adults is significantly longer than in
children, which may partly be due to less typical HLH mani-
festations in adult patients. Our investigation strongly suggests
that the diagnosis of HLH needs to be kept in mind when
encountering an adult patient presenting with fever, thrombocy-
topenia, an elevated serum ferritin level, and liver dysfunction.
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